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CDKN2A locus on chromosome 9p21 encodes two tumour suppressor proteins pl6
INK4A, which is a regulator of the retinoblastoma
(RB) protein, and p14
ARF, which is involved in the ARF–Mdm2–p53 pathway. The aim of this study was to determine if CDKN2A
gene products are implicated in differentiated thyroid carcinogenesis and progression. We used real-time quantitative RT–PCR and
immunohistochemistry to assess both transcripts and proteins levels in 60 tumours specimens. Overexpression of p14
ARF and
pl6
INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in
oncocytic adenomas compared to nontumoral paired thyroid tissues. These deregulations were statistically significant for pl6
INK4a
(P¼0.006) in follicular adenomas and close to statistical significance for p14
ARF in follicular adenomas (P¼0.06) and in papillary
carcinomas (P¼0.05). In all histological types, except papillary carcinomas, we observed a statistically significant relationship between
p14
ARF and E2F1 (r¼0.64 to 1, Po0.05). Our data are consistent with involvement of CDKN2A transcript upregulation in thyroid
follicular tumorigenesis as an early event. However, these deregulations do not appear to be correlated to the clinical outcome and
they could not be used as potential prognostic markers.
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Tumours arising from the thyroid follicular epithelium are
regarded as a unique model to study human carcinogenesis
because, while they all derive from thyrocytes, they have different
clinical and histological features (reviewed in Gimm, 2001).
Papillary (PTC) and follicular thyroid (FTC) cancers are well-
differentiated tumours, which maintain some morphological
features of the normal thyroid, and are, most of the time,
responsive to radioiodine treatment (Vini and Harmer, 2002). In
contrast, anaplastic thyroid cancers are undifferentiated neoplasias
with a more aggressive behaviour (Giuffrida and Gharib, 2000).
They have lost any significant resemblance with the structural
organisation of a normal thyroid follicle, and are unresponsive to
both radioactive iodine treatment and chemotherapeutic agents
(reviewed in Gimm, 2001). From a molecular standpoint, well-
differentiated thyroid cancers are recognised to be initiated by
genetic events that involved the improper activation of cellular
proto-oncogenes (Pierotti et al, 1996). Up to 60% of papillary
thyroid carcinomas present either BRAF mutations or rearrange-
ments in the RET or NTRK1 tyrosine kinase genes with a plethora
of activating genes that are considered to represent the first step
in tumour development (Santoro et al, 1996; Greco et al, 1997,
reviewed in Xing, 2005). In 35% of follicular thyroid carcinomas,
neoplastic transformation is triggered by activating mutations
of the RAS gene or by the fusion of the PAX8 transcription factor
with the gene encoding for peroxisome proliferator-activated
receptor (Fagin, 2000; Kroll et al, 2000). Some of the genetic events
responsible for the development of well-differentiated thyroid
cancers have been identified; loss of heterozygosity in several
chromosomal regions (1p, 3p, 3q, 10q, 11p, 13q and 22q) has been
reported in papillary and follicular carcinomas (Ward et al, 1998;
Kitamura et al, 2000a,b). The only established genetic alteration
involved in the dedifferentiation process leading to anaplastic
thyroid tumour development is the loss of the p53 tumour
suppressor gene (Fagin et al, 1993).
CDKN2A locus on chromosome 9p21 (reviewed in Sherr, 2001)
encodes two proteins. INK4A (also referred to as pl6
INK4A)
specially blocks the CDK4 and CDK6 cyclin-dependent kinases
that control the phosphorylation status of the retinoblastoma (RB)
protein (Serrano et al, 1993). ARF (known as p14
ARF in man and
p19
ARF in mouse) has been designed as a positive regulator of p53
levels because, through its complexation with Mdm2 (HDM2 in
human), it prevents mdm2-mediated cytoplasmic translocation
and degradation of p53 (Kubbutat et al, 1997). For this reason,
ARF is considered to be an important factor of the so-called
ARF–Mdm2–p53 pathway, that is activated by potential oncogenic
signals such as oncogenic ras protein, E1A and v-Abl oncoproteins
and ectopic expression of both c-myc and E2F1 (Sherr, 1998).
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ARF could inhibit cell proliferation independently of p53. For
example, introduction of ARF into cells devoid of any functional
p53 and Mdm2 proteins results in cell proliferation arrest (Carnero
et al, 2000; Weber et al, 2000). Moreover, p14
ARF inhibits the
growth of p53 nullizygous human tumours in nude mice and
induces the regression of p53 /  established tumours (Eymin
et al, 2003).
The ARF locus is frequently impaired (in conjunction with the
INK4A gene) in a variety of human primary tumours, indicating
that disruption of this locus is essential for deregulating cell
proliferation. However, implication of the p16
INK4A and p14
ARF has
not been clearly defined in thyroid cancer development and
progression. The present study was aimed at evaluating possible
relationship between the p16
INK4A and p14
ARF expression on the
one hand, and both clinical and pathological features of thyroid
carcinomas on the other hand, by using quantitative RT–PCR and
immunohistochemistry approaches.
MATERIALS AND METHODS
Patients and samples
A total of 102 thyroid tissue samples from 60 patients were
processed, including 31 papillary carcinomas, five follicular
carcinomas, 10 follicular adenomas, 14 oncocytic adenomas and
42 nontumoral thyroid tissue samples adjacent to carcinomas or
adenomas. Tissue samples were obtained from the frozen tissue
bank of the pathology department of Poitiers University Hospital.
Specimen collection was performed in accordance with the
Declaration of Helsinki. Tumour specimens were snap frozen in
liquid nitrogen and stored at  801C until processed for RNA
extraction.
All patients were treated at Department of Endocrine Surgery
of Poitiers, between 1998 and 2002. They underwent surgical
treatment such as unilateral lobectomy, isthmolobectomy or total
thyroidectomy according to clinical data. Clinicopathological data
of the 60 patients was summarised in Table 1. AGES (age, grade
(according to Broder’s classification) tumour extent (local invasion
and distant metastases) size of the primary tumour) prognostic
scores were calculated and patients were included in minimal
(score of 0–3.99) or higher risk groups (score of 4 and more) as
described by Hay et al (1987).
RNA extraction and cDNA preparation
Total RNAs were extracted from tumour specimens using Qiagen
RNeasy
s Mini Kit according to the manufacturer’s instructions
with minor modifications: for exclusion of contaminating genomic
DNA, the spin–column membranes were treated with DNase
(Qiagen, Courtaboeuf Cedex, France) for 15min on the bench top
before elution. DNase-treated total RNA (3mg) was transcribed
into cDNA using Superscriptt II RnaseH- and random hexamers
(Invitrogen).
Quantitative real-time RT–PCR (QRT–PCR)
We assessed mRNA levels of p14
ARF, p16
INK4A, and E2F1 relative to
GAPDH in 102 thyroid tissue by using quantitative real time PCR
(QRT–PCR) in the ABIPRISM 7000 Sequence Detection System
and the human p14
ARF, p16
INK4a, E2F1 and GAPDH Taqman Pre-
Developed Taqman
s Assay Reagents (Applied Biosystems, Foster
city, CA, USA). The amplification of p14
ARF, p16
INK4A, E2F1 and
GAPDH cDNA was carried out in 25ml reaction volume consisting
in 1  Taqman Universal PCR Master-Mix and 1.25ml of Pre-
Developed Taqman
s Assay Reagents (900nm primers and 200nM
probe) (Applied Biosystems). The reaction was performed as
follows: 501C for 2min, 951C for 10min followed by 40 cycles at
951C 15s, 601C 1min. Each sample was tested in duplicate and
a negative control was included in every plate. The computed
tomography value was defined as the cycle number (Ct) at which
the fluorescence crossed the threshold. The results were expressed
in DCt (CtGAPDH–Ctgene)o ri n2  DCt
*1000 for the amount of the
target normalised and relative to the endogenous reference.
Immunohistochemistry
Immunostaining was performed on 15 papillary carcinomas, five
follicular carcinomas, 10 follicular adenomas and nontumoral
thyroid tissue samples adjacent to thyroid tumours for each
patient. The surgical specimen were fixed in formalin, paraffin
embedded and cut in 5mm tissue sections placed on charged slides.
Slides were deparaffinised, rehydrated and microwaved in 10mM
citrate buffer pH 6.0 for antigen retrieval. Immunohistochemistry
was performed using mouse monoclonal antibodies directed
against p14 ARF (Clone H-132) and p16 INK4A (Clone F12) (Santa
Cruz Biotechnology, CA, USA) at 1:200 dilution. After blocking
for endogenous peroxidase with 1% hydrogene peroxide, the
primary antibodies were incubated at 41C overnight. Immuno-
staining was performed using the Immunotech automated
immunohistochemistry system (Microm Microtech, France). The
automated procedure is based on an indirect biotin–avidin system
with a universal biotinylated immunoglobulin secondary antibody,
diaminobenzidin substrate and haemetoxylin counterstain.
Negative controls were obtained by incubation with an immuno-
globulin class-matched no immune antibody (mouse monoclonal
Table 1 Characteristics of patients and tumours
All patients Oncocytic adenomas Follicular adenomas Follicular carcinomas Papillary carcinomas
n patients 60 14 10 5 31
Mean age (years) 48.2 (20–92) 48.1 (26–69) 41.6 (20–73) 61.2 (23–92) 48.3 (22–90)
Mean tumour size (mm) 24 (4–100) 30 (12–58) 31 (13–72) 27 (15–40) 19 (4–100)
Multicentricity 17 (23.8%) 8 (57%) 2 (20%) 1 (20%) 6 (19.35%)
Nodal metastasis — — — 1N+ (20%) 3N+ (9.7%)
Juxtathyroid invasion — — — 2 (40%) 6 (19.35%)
Visce ´ral metastasis — — — 0 0
Tumour grade
1 — — — 2 (40%) 29 (93.54%)
2 — — — 2 (40%) 1 (3.23%)
3 — — — 1 (20%) 1 (3.23%)
AGES score o4 — — — 2 (40%) 26 (83.87%)
AGES score X4 — — — 3 (60%) 5 (16.13%)
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simmunoglobulin, Dakocytomation, Denmark). Positive controls
were obtained by immunostaining on reactive lymph nodes, as
previously described (Paik et al, 2005).
Scoring of antibody staining
Scoring of antibody staining was performed by pathologist G
Fromont who was blind to gene expression status obtained by
QRT–PCR. A specimen was considered positive for p14
ARF or
p16
INK4A if there was nuclear staining above any cytoplasmic
background. Cytoplasmic staining itself was noted but not
included in the scoring (Geradts et al, 2001). The immunohisto-
chemical results were evaluated using a semiquantitative analysis:
no staining reaction¼0, o10% positive-stained cells¼þ,1 0 –
80% positive cells or focal staining¼þþ, 480% positive cells
with diffuse staining¼þþþ.
Statistical analysis
The data distribution of normalised expression levels of tissue
samples is non-Gaussian. So, nonparametric tests were applied for
data analysis. The Wilcoxon test was used for comparing tumour
tissue to its own nontumoral paired tissue or to mean of the 42
paired tissue expression levels when no paired tissue was available.
Upregulation or downregulation was defined by the ratio value
between expression level in tumoral tissue and in nontumoral
paired tissue (T/S¼2 DCt tumor/2 DCtnormal tissue). A normal
interval was defined for this ratio by the 95% confidence interval of
mean for normal tissues and was 0.71–1.32 for p14
ARF, 0.7–1.40
for p16
INK4A, 0.85–1.18 for E2F1. For correlations between
expression levels and clinicopathological data, the Spearman
test was used. P-values o0.05 were considered statistically
significant.
RESULTS
p14
ARF, p16
INK4A expression in thyroid malignancies
In this work we determined the expression of p14
ARF and p16
INK4A
in 60 thyroid tumours and compared them to their nontumoral
paired thyroid tissue control. In all, 18 thyroid tumours without
nontumoral paired thyroid tissue control were compared to mean
expression of the 42 nontumoral tissues available. We observed
an overexpression of p16
INK4A and p14
ARF transcripts in follicular
adenomas, follicular carcinomas and papillary carcinomas and a
downregulation in oncocytic adenomas (Figure 1 and Table 2).
This overexpression in follicular adenomas was statistically
significant for p16
INK4A (P¼0.006) and almost reached statistical
significance for p14
ARF (P¼0.06). In follicular carcinomas and
oncocytic adenomas, we observed, respectively, an upregulation
and a downregulation of p14
ARF and p16
INK4A expression. Also
suggestive, these data were not statistically significant probably
because of the too low number of tumour samples analysed
(Figure 1 and Table 2). In papillary carcinomas, the expression of
p14
ARF and p16
INK4A was heterogeneous with equal proportions of
tumours overexpressing or downexpressing p14
ARFor p16
INK4A.
The observed deregulation of these two transcripts was close to
statistical significance (P¼0.05 and P¼0.09) for p14
ARF and
p16
INK4A, respectively (Figure 1 and Table 2).
We studied the protein expression level of p14
ARF and p16
INK4a
by immunohistochemistry on papillary carcinomas (n¼15),
follicular adenomas (n¼10) and follicular carcinomas (n¼5).
Results are summarized in Table 3.
In follicular adenomas, p14
ARF protein was found to be
overexpressed in six cases when compared to nontumoral tissue
and p16
INK4A in four cases according to QRT–PCR data,
(Figure 2A and Table 3). The other cases show identical
immunostaining compared to nontumoral tissue. Overexpression
of p14
ARF and p16
INK4A was identified in only one follicular
carcinoma, case 13 (Table 3). As in follicular adenomas, the other
cases shows identical immunostaining compared to nontumoral
tissue. No underexpression of both p14
ARF and p16
INK4A was
observed by immunohistochemistry in follicular tumours.
Among the nine papillary carcinomas that overexpressed p14
ARF
by QRT–PCR, four showed increased nuclear expression of p14
ARF
by immunohistochemistry, and interestingly five displayed a
cytoplasmic delocalization of the protein (Figure 2B and Table 3).
When p16
INK4A expression increased by QRT–PCR, immunohis-
tochemical nuclear staining was increased in one case, unchanged
in one case, and was localised to the cytoplasm in six cases.
Decreased expression of both p14
ARF and p16
INK4A by QRT–PCR
in papillary carcinoma was associated in majority either with
decreased or identical immunostaining when compared to normal
tissue, or with increased staining in two cases.
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Figure 1 Box plot diagrams showing the expression levels of p14
ARF, p16
INK4A and E2F1. After normalization of sample to their own GAPDH level, data
are expressed in 2
 2 DCt
*1000. OA: oncocytic adenomas; FA: follicular adenomas; FC: follicular carcinomas; PC: papillary carcinomas.
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in nontumoral tissues, and expressed both p14
ARF and p16
INK4A.
Finally, no significant correlation has been found between
p14
ARF and p16
INK4A mRNA levels and clinicopathological
prognostic markers, such as stage, grade, histological subtype,
age, node metastasis or AGES score.
p14
ARF regulation by E2F1 is lost in papillary carcinomas
We examined the relationships between mRNA levels p14
ARF,
p16
INK4A and E2F1 expression. For this we determined first the
mRNA expression levels of E2F1 in the same tumours. Consistent
with others studies, E2F1 levels were upregulated in all tumour
Table 2 Expression levels of p14
ARF, p16
INK4A and E2F1 in nontumoral and in tumoral tissues according to histological type
Nontumoral tissue
(n¼42)
Oncocytic
adenoma (n¼14)
Follicular adenoma
(n¼10)
Follicular carcinom
(n¼5)
Papillary carcinoma
(n¼31)
mRNA expression
levels
p14
ARF 1.14 (0.13–9.1) 0.58 (0.025–3.02)
(P¼1)
1.42 (0.45–5.41)
(P¼0.06)
2.20 (1.39–24.35)
(P¼0.12)
1.80 (0.14–23.85)
(P¼0.05)
p16
INK4A 1.11 (0.05–9.04) 0.73 (0.009–2.21)
(P¼0.54)
2.30 (0.83–9.55)
(P¼0.006)
4.10 (1.07–28.75)
(P¼0.19)
1.61 (0.12–52.92)
(P¼0.09)
E2F1 2.15 (0.68–7.04) 1.89 (0.86–6.75)
(P¼0.27)
2.81 (1.30–11.28)
(P¼0.08)
3.42 (1.03–6.39)
(P¼0.19)
3.24 (1.06–17.58)
(P¼0.0001)
The results (medians and minims–maxims) are expressed in 2 DCt*1000 where DCt¼CtGAPDH–Ctgene. The Wilcoxon test was used to compare the expression levels between
nontumoral and tumoral tissues. Po0.05 is considered statistically significant. Statistically relevant P-values are in bold.
Table 3 Immunohistochemical analysis for p14
ARF and p16
INK4A in normal tissue (N) and thyroid tumours (T) and comparison with their mRNA levels
mRNA levels
IHC
MRNA levels
IHC
p14
ARF T/N p14
ARF N p14
ARF T p16
INK4 T/N p16
INK4 N p16
INK4 T
Follicular adenomas
Case 1 2.5 + +++ 2.3 ++ +++
Case 2 2.5 ++ +++ 1.4 +++ +++
Case 3 7.5 + ++ 9.1 + ++
Case 4 15.5 0 ++ 11.5 +++ +++
Case 5 0.8 + + 1.2 +++ +++
Case 6 1.3 ++ ++ 4.2 ++ ++
Case 7 0.5 ++ ++ 1.3 ++ ++
Case 8 1.2 ++ +++ 2.1 ++ +++
Case 9 0.7 ++ ++ 0.7 +++ +++
Case 10 3.3 + ++ 7.4 + ++
Follicular carcinomas
Case 11 1 ++ ++ 0.85 ++ ++
Case 12 4.2 +++ +++ 3.8 +++ +++
Case 13 3.9 ++ +++ 4 ++ +++
Case 14 1.9 +++ +++ 1.1 +++ +++
Case 15 22.6 +++ +++ 28.3 +++ +++
Papillary carcinomas
Case 16 24.3 ++ +++ 17.2 NA NA
Case 17 2.6 + +++ 1.2 ++ ++
Case 18 6.3 + 0 (+C) 2.7 ++ 0 (+C)
Case 19 3.1 + + (+C) 2.1 + + (+C)
Case 20 0.5 ++ ++ 0.7 ++ ++
Case 21 0.1 +++ ++ 0.1 ++ 0
Case 22 0.6 ++ + 0.2 NA NA
Case 23 2.2 +++ + (+C) 1.6 ++ + (+C)
Case 24 0.3 ++ +++ 0.3 ++ +++
Case 25 1.2 ++ ++ 1.7 ++ ++ (+C)
Case 26 0.3 ++ +++ 0.5 ++ +++
Case 27 9.4 ++ +++ 25.9 +++ +++
Case 28 5.5 ++ ++ (+C) 4.8 ++ ++ (+C)
Case 29 19.3 ++ ++ (+C) 21.7 ++ ++ (+C)
Case 30 11.3 0 +++ 7.4 ++ +++
The immunohistochemical results were evaluated using a semiquantitative analysis: no staining reaction¼0, o10% positive-stained cells¼+, 10–80% positive cells or focal
staining¼++, 480% positive cells with diffuse staining¼+++. Increased expression appeared in red, decreased expression in green and cytoplasmic localisation in blue.
Transcriptional upregulation or downregulation was defined by the ratio value between expression level in tumoral tissue and in normal paired tissue( T/S¼2 DCttumour/
2 DCtnormal tissue). A normal interval was defined for this ratio by the 95% confidence interval of mean for normal tissues and was 0.71–1.32 for p14
ARF, 0.7–1.40 for p16
INK4A
(NA¼not analysed).
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stypes (Onda et al, 2004). This upregulation was statistically
significant in PTC (P¼0.0001) (Table 2 and Figure 1). A strong
correlation occurred between p14
ARF and p16
INK4A in normal
tissue (r¼0.65, Po0.0001) as well as in tumoral tissues (r¼0.65–
0.89 depending on tumour type, Po0.05). E2F1 is known to
positively regulate p14
ARF expression (Bates et al, 1998). Indeed,
such a relationship was observed between p14
ARF and E2F1
expression in normal (r¼0.41, P¼0.01) and tumour tissues
(r¼0.64 to 1, Po0.05) except for papillary carcinomas (r¼0.04,
P¼0.86) (Table 4).
DISCUSSION
The purpose of this study was to analyse p14
ARF and p16
INK4A
mRNA and protein levels in various thyroid tumours including
oncocytic adenomas, follicular adenomas, follicular carcinomas
and papillary carcinomas. A high prevalence of upregulation for
both p14
ARF and p16
INK4A transcripts was found in follicular
adenomas and carcinomas. We observed an heterogenous profiling
papillary carcinomas (45% overexpress p14
ARF and p16
INK4A
transcripts and 45% downexpress these transcripts). In the
N  T
T
 p14ARF X10
 p14ARF X10  p14ARF X20
 p14ARF X20  p14ARF X20
 p14ARF X40
N 
p16INK4A X20  p16INK4A X10 
N 30  T 30 
 N 23  T 23 
A
B
Figure 2 Immunohistochemical detection for p14
ARF and p16
INK4A.( A) Follicular adenoma, case 1: Increased p14
ARF and p16
INK4A expression in tumour
(T) when compared to nontumoral tissue (N). (B) Papillary carcinoma, case 30: increased nuclear p14
ARF expression in tumor (T30) when compared to
nontumoral tissue (N30). Case 23: cytoplasmic delocalisation of p14
ARF in tumour (T23), when compared to nontumoral (N23). N: nontumoral adjacent
tissue, T: Tumour.
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smajority of oncocytic adenomas, we observed a downregulation of
p14
ARF and p16
INK4A.
We observed a concordance between mRNA and protein levels
in most of tumours tested: 80% (24 out of 30) cases for p14
ARF and
78.5% (22 out of 28) cases for p16
INK4A when cytoplasmic staining
observed in papillary carcinomas is taken into account. In 20% of
tumors, protein expression did not reflect mRNA status for both
p14
ARF and p16
INK4A. This apparent uncoupling have been
previously reported on haematopoietic human cell lines (Della
Valle et al, 1997 ) and on small-cell lung tumours (Gazzeri et al,
1998).
In the majority of the previously documented cases, the
discrepancies between mRNA and protein expression corresponds
to overexpression of mRNA and normoexpression of the
protein. As some patients (particularly cases 4, 12, 15 and 27)
showed a high expression of p14
ARF and/or p16
INK4A in
nontumoral tissue, it was difficult to evidence any increase in
tumoral tissue. Moreover, the heterogeneity of gene expression
within the normal or tumoral tissue must also be taken into
account. The presence of a lymphoid infiltrate, which expressed
both p14
ARF and/or p16
INK4A, mainly in nontumoral tissue, can
also explain some discordant results because positive lymphocytes
were not included in IHC scoring. At the end, we should also take
into account that accumulation or depletion of transcripts could
result from an increased or decreased stability. Regarding this
point, impaired mRNA turnover and stability are shown to play a
critical role in the activation of specific genes during the cellular
response to mitogens, stressful stimuli and differentiation agents
(Bashirullah et al, 2001; Fan et al, 2002). Interestingly, we observed
in six cases of papillary carcinoma a cytoplasmic localisation of
both p14
ARF and p16
INK4A. This localisation is unusual for these
proteins and suggest that in these cases p14
ARF and p16
INK4A could
not be efficients.
Our results are consistent with others studies. Ferenc et al (2004)
reported such an upregulation by use of a tissue array technology.
Intensity of p16
INK4A staining tended to increase from follicular
adenoma to follicular carcinoma compared to normal tissue.
Moreover, others found no mutation and no loss of heterozygosity
for the MTS1 locus (that encodes both p16
INK4A and p14
AR) in dif-
ferentiated carcinomas (Calabro et al, 1996; Schulte et al, 1998;
Ward et al, 1998; Kitamura et al, 2000a,b). In contrast, Boltze et al
(2003) found hypermethylation of p16
INK4a in 33% of follicular
adenomas, in 44% of papillary carcinomas, in 50% of follicular
carcinomas that correlated with loss of p16
INK4a.
Taken together, these data, including our own results,
suggest that the inactivation of p16
INK4A/p14
ARF locus in these
carcinomas is rare and that in contrast, the upregulation of these
genes could be associated with thyroid cancer progression.
Both p16
INK4A and p14
ARF proteins are tumour suppressors and
it is their loss not their gain that should contribute to
tumorigenesis. However, the increased expression of CDKN2a
gene products alpha (p16
INK4A) and beta (p14
ARF) has been
described to be associated with progression and unfavourable
prognosis in different tumour types. For instance, the increased
expression of p16
INK4A has been described to be associated with
progression and unfavourable prognosis in ovarian cancer (Dong
et al, 1997), in high-grade prostatic intraepithelial neoplasia
(Henshall et al, 2001) and in primary breast cancer (Hui et al,
2000). Also, the upregulation of p14
ARF is mainly seen in
haematological malignancies (Lee et al, 2003) and in aggressive
B-cell lymphomas, and it predicts a shortened survival time
(Sanchez-Aguilera et al, 2002).
The overexpression of p14
ARF/p16
INK4A tumour suppressor
genes could be explained by several known data. Regarding the
expression of p16
INK4A, the most well-defined mechanism of
p16
INK4A overexpression is the loss of transcriptional repression
in the presence of inactivating mutations in the RB gene (Ruas
and Peters, 1998). It has been suggested that p16
INK4A-mediated
growth inhibition may occur only when cyclin E/Cdk2 complexes
are inactivated concurrently by the cell cycle inhibitor p27
KIP1
(Lukas et al, 1997; Jiang et al, 1998). In this regard, the MDA-MB-
157 breast cancer cell line retains functional pRB but can
proliferate in the presence of p16
INK4A overexpression (Sweeney
et al, 1998). Furthermore, others have observed RAS and Rb
mutations in 40–50% of follicular adenomas and carcinomas
(Suarez et al, 1990; Capella et al, 1996; Zou et al, 1998) and a
downregulation of p27
KIP1, which was correlated with tumoral
progression (Erickson et al, 2000; Troncone et al, 2000). Although
we did not examine RB or Ras mutations, neither p27
Kip1 status in
our tumour cohort, these data could explain the p16
INK4A
upregulation we observed.
Regarding the expression of p14
ARF, its expression is induced
by oncogenes like myc, ras or viral genes (Palmero et al, 1998).
E2F1 is a well-known transcriptional regulator of p14
ARF as p14
ARF
promoter has an E2F1-binding site (Bates et al, 1998). Every
cancer-related defect in these pathways should result in p14
ARF
upregulation. We found an upregulation of E2F1 in all tumour
types which is consistent with others studies (Saiz et al, 2002; Onda
et al, 2004), and we observed a link between E2F1 and p14
ARF
expression in nontumoral thyroid tissue as well as in follicular
adenomas and carcinomas. These results suggest the involvement
of E2F1 in the p14
ARF upregulation in these tumours. The link
between E2F1 and p14
ARF expression found in nontumoral thyroid
tissue was no more present in papillary carcinomas. Strikingly,
E2F1 mRNA level was upregulated in all papillary carcinomas,
while 45% of them showed a downregulation of p14
ARF suggesting
that transcriptional regulation of p14
ARF in these tumours is
independent of E2F1.
Because of their cytoplasmic localisation, these overexpressions
of the two proteins are probably nonfunctional. When they are,
at first glance, nuclear, their overexpression seems, however, not
sufficient to inhibit cell proliferation during the process of thyroid
tumorigenesis.
In contrast, in majority of oncocytic adenomas we observed a
downregulation of p14
ARF. As these tumours showed also more
frequently decreased expression of E2F1 than other histological
Table 4 mRNA levels correlations between p14
ARF, p16
INK4A and E2F1 genes in nontumoral and in tumour tissues according to histological type
Normal tissue
Oncocytic
adenomas
Follicular
adenomas
Follicular
carcinomas
Papillary
carcinomas
mRNA level
correlations
p14
ARF and p16
INK4A r¼0.65 r¼0.78 r¼0.65 r¼0.80 r¼0.89
Po0.0001 P¼0.001 P¼0.04 P¼0.01 Po0.0001
p14
ARF and E2F1 r¼0.41 r¼0.63 r¼0.68 R¼1 r¼0.04
P¼0.01 P¼0.015 P¼0.029 Po0.0001 P¼0.86
p16
INK4A and E2F1 r¼0.21 r¼0.7 r¼0.48 r¼0.80 r¼ 0.09
P¼0.20 P¼0.005 P¼0.16 P¼0.1 P¼0.66
The Spearman rank test was used. The correlation coefficient (r) is given with P. Po0.05 is considered statistically significant. Statistically relevant P-values are in bold.
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ARF was noted, this
suggests that downregulation of p14
ARF could be linked to the
downregulation of E2F1 in this tumour type.
To conclude, we observed that p14
ARF and p16
INK4A expression
levels are different according to histological type of thyroid
tumours. Upregulation seems to be implicated in thyroid follicular
carcinogenesis as an early event and could be considered as
tumourprogression marker. Papillary carcinomas displayed a
more complex pattern with a great heterogeneity for p14
ARF,
p16
INK4A expression and an E2F1-independent transcriptional
regulation. However, these deregulations are not correlated to the
clinical outcome and they could not be used as potential
prognostic markers alone.
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